Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05000957 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pelvic Organs Prolapse Treatment Using Neodymium Laser

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 12, 2024 (before its estimated April 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion date: Apr 1, 2024 to Apr 1, 2025v10 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 135 to confirmed 129
    • Site details revised
    • Study description expanded, about 5 words
  2. Notable Primary completion date: May 1, 2023 to Apr 1, 2024
    • Study completion date: Aug 1, 2023 to Apr 1, 2025
    v9
  3. Minor Study description expanded, about 25 wordsv8
  4. Minor Study description revisedv7
  5. Notable Primary completion date: Aug 1, 2022 to May 1, 2023v6
Show 4 earlier versionsHide 4 earlier versions
  1. Minor Interventions: Anterior and/or posterior colporrhaphy (Procedure), Biopsy of the vaginal wall (Diagnostic Test), Blood analysis (Diagnostic Test)… to Anterior and/or posterior colporrhaphy (Procedure), Biopsy of the vaginal wall (Diagnostic Test), Blood analysis (Diagnostic Test), Buccal…
    • Study description expanded, about 139 words
    • Site contact updated
    v5
  2. Minor Re-verified, no change to tracked fieldsv4
  3. Minor Start date: Oct 4, 2021 to Oct 3, 2021v3
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Aug 16, 2021 to Oct 4, 2021
    • Site details revised
    v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this prospective study is investigation of efficiency and safety of medical device "Magic Max" ("Magic Gyno" from August 2024) for preoperative treatment of pelvic organs prolapse I-II degree of severity. To assess the condition of the vaginal walls and vulva before and after laser treatment, the following methods will be used: ultrasonography with Doppler ultrasonography, vaginal health index, histological examination, immunohistochemical examination, optical coherence tomography (OCT) (elastography). Pelvic Floor Distress Inventory Questionnaire (PFDI-20), The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12), International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF), Pelvic Floor Impact Questionnaire (PFIQ-7) will be used to collect feedback on changes in the participants life quality. Genetic testing of 12 gene variants will be carried out. Correlation of genes variants and treatment efficacy will be assessed. Total up to 135 participants with pelvic organs prolapse I-II degree of severity, or any other pathology of pelvic organs, which require surgical intervention will be involved in the study. Participants will be divided into three groups: group with anterior and/or posterior (A/P) colporrhaphy and laser preoperative treatment (laser treatment group), group with A/P colporrhaphy only (control group 1), and group with any other surgical intervention of pelvic area (control group 2), by 45 participants in each. The time intervals between tests will be the same for groups with A/P colporrhaphy, group with any other surgical intervention will be examined before and on the day of surgery without further observation. The main hypothesis of the study is improvement in condition of the vaginal walls after laser preoperative treatment compared with the control group 1.
Trial Details
NCT Number NCT05000957
Lead Sponsor MeLSyTech, Ltd
Conditions
(from sponsor)
Pelvic Organ Prolapse, Female Urogenital Diseases
Related terms Female Urogenital Diseases, Pelvic Organ Prolapse
Enrollment 129 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov